Advances and challenges in therapeutic monoclonal antibodies drug development
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/153906 |
Resumo: | The use of serum containing polyclonal antibodies from animals immunized with toxins marked the beginning of the application of antibody-based therapy in late nineteenth century. Advances in basic research led to the development of the hybridoma technology in 1975. Eleven years later, the first therapeutic monoclonal antibody (mAb) was approved, and since then, driven by technological advances, the development of mAbs has played a prominent role in the pharmaceutical industry. In this review, we present the developments to circumvent problems of safety and efficacy arising from the murine origin of the first mAbs and generate structures more similar to human antibodies. As of October 2017, there are 61 mAbs and 11 Fc-fusion proteins in clinical use. An overview of all mAbs currently approved is provided, showing the development of sophisticated mAbs formats that were engineered based on the challenges posed by therapeutic indications, including antibody-drug conjugates (ADC) and glycoengineered mAbs. In the field of immunotherapy, the use of immunomodulators, bispecific mAbs and CAR-T cells are highlighted. As an example of promising therapy to treat infectious diseases, we discuss the generation of neutralizing monoclonal-oligoclonal antibodies obtained from human B cells. Scientific and technological advances represent mAbs successful translation to the clinic. |
id |
USP-31_55931a377446379fd8c6b700ad24cb06 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/153906 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Advances and challenges in therapeutic monoclonal antibodies drug developmentImmunotherapyCDR graftingPhage displayTransgenic miceSingle B cell sortingThe use of serum containing polyclonal antibodies from animals immunized with toxins marked the beginning of the application of antibody-based therapy in late nineteenth century. Advances in basic research led to the development of the hybridoma technology in 1975. Eleven years later, the first therapeutic monoclonal antibody (mAb) was approved, and since then, driven by technological advances, the development of mAbs has played a prominent role in the pharmaceutical industry. In this review, we present the developments to circumvent problems of safety and efficacy arising from the murine origin of the first mAbs and generate structures more similar to human antibodies. As of October 2017, there are 61 mAbs and 11 Fc-fusion proteins in clinical use. An overview of all mAbs currently approved is provided, showing the development of sophisticated mAbs formats that were engineered based on the challenges posed by therapeutic indications, including antibody-drug conjugates (ADC) and glycoengineered mAbs. In the field of immunotherapy, the use of immunomodulators, bispecific mAbs and CAR-T cells are highlighted. As an example of promising therapy to treat infectious diseases, we discuss the generation of neutralizing monoclonal-oligoclonal antibodies obtained from human B cells. Scientific and technological advances represent mAbs successful translation to the clinic.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2018-12-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/15390610.1590/s2175-97902018000001007Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. Especial (2018); e01007Brazilian Journal of Pharmaceutical Sciences; v. 54 n. Especial (2018); e01007Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. Especial (2018); e010072175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/153906/150236Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessSantos, Mariana Lopes dosQuintilio, WagnerManieri, Tania MariaTsuruta, Lilian RumiMoro, Ana Maria2019-03-17T12:32:06Zoai:revistas.usp.br:article/153906Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2019-03-17T12:32:06Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Advances and challenges in therapeutic monoclonal antibodies drug development |
title |
Advances and challenges in therapeutic monoclonal antibodies drug development |
spellingShingle |
Advances and challenges in therapeutic monoclonal antibodies drug development Santos, Mariana Lopes dos Immunotherapy CDR grafting Phage display Transgenic mice Single B cell sorting |
title_short |
Advances and challenges in therapeutic monoclonal antibodies drug development |
title_full |
Advances and challenges in therapeutic monoclonal antibodies drug development |
title_fullStr |
Advances and challenges in therapeutic monoclonal antibodies drug development |
title_full_unstemmed |
Advances and challenges in therapeutic monoclonal antibodies drug development |
title_sort |
Advances and challenges in therapeutic monoclonal antibodies drug development |
author |
Santos, Mariana Lopes dos |
author_facet |
Santos, Mariana Lopes dos Quintilio, Wagner Manieri, Tania Maria Tsuruta, Lilian Rumi Moro, Ana Maria |
author_role |
author |
author2 |
Quintilio, Wagner Manieri, Tania Maria Tsuruta, Lilian Rumi Moro, Ana Maria |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Santos, Mariana Lopes dos Quintilio, Wagner Manieri, Tania Maria Tsuruta, Lilian Rumi Moro, Ana Maria |
dc.subject.por.fl_str_mv |
Immunotherapy CDR grafting Phage display Transgenic mice Single B cell sorting |
topic |
Immunotherapy CDR grafting Phage display Transgenic mice Single B cell sorting |
description |
The use of serum containing polyclonal antibodies from animals immunized with toxins marked the beginning of the application of antibody-based therapy in late nineteenth century. Advances in basic research led to the development of the hybridoma technology in 1975. Eleven years later, the first therapeutic monoclonal antibody (mAb) was approved, and since then, driven by technological advances, the development of mAbs has played a prominent role in the pharmaceutical industry. In this review, we present the developments to circumvent problems of safety and efficacy arising from the murine origin of the first mAbs and generate structures more similar to human antibodies. As of October 2017, there are 61 mAbs and 11 Fc-fusion proteins in clinical use. An overview of all mAbs currently approved is provided, showing the development of sophisticated mAbs formats that were engineered based on the challenges posed by therapeutic indications, including antibody-drug conjugates (ADC) and glycoengineered mAbs. In the field of immunotherapy, the use of immunomodulators, bispecific mAbs and CAR-T cells are highlighted. As an example of promising therapy to treat infectious diseases, we discuss the generation of neutralizing monoclonal-oligoclonal antibodies obtained from human B cells. Scientific and technological advances represent mAbs successful translation to the clinic. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-12-28 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/153906 10.1590/s2175-97902018000001007 |
url |
https://www.revistas.usp.br/bjps/article/view/153906 |
identifier_str_mv |
10.1590/s2175-97902018000001007 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/153906/150236 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. Especial (2018); e01007 Brazilian Journal of Pharmaceutical Sciences; v. 54 n. Especial (2018); e01007 Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. Especial (2018); e01007 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222913839759360 |